Tvardi Therapeutics, Inc. (TVRD) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tvardi Therapeutics, Inc. (TVRD) closed at USD 1.00 on 2026-10-14, a change of -78.8 % over the past year, with a market capitalization of USD 14.27M.

Tvardi Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tvardi Therapeutics, Inc. key figures

Previous close

USD 1.00 (2026-10-14)

1-year change

-78.8 %

Market cap

USD 14.27M

Enterprise value

USD -1.35M

P/E ratio (trailing)

-0.37

P/E ratio (forward)

-0.48

EPS (trailing)

-2.91

EPS (forward)

-2.24

PEG ratio

n/a

Price to book

1.20

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.09

Employees

12

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tvardi Therapeutics, Inc. and compare it with other stocks.